Could This Be The Big Alzheimer’s Disease Breakthrough?
A piece in Science Daily describes a study in which a drug approved by the FDA for other purposes was administered to Alzheimer’s disease patients with startling results:
The authors hypothesized that elevated levels of TNF in Alzheimer’s disease interfere with this regulation [of neural impulses in the brain]. To reduce elevated TNF, the authors gave patients an injection of an anti-TNF therapeutic called etanercept. Excess TNF-alpha has been documented in the cerebrospinal fluid of patients with Alzheimer’s. . . The new study documents a dramatic and unprecedented therapeutic effect in an Alzheimer’s patient: improvement within minutes following delivery of perispinal etanercept, which is etanercept given by injection in the spine. Etanercept (trade name Enbrel) binds and inactivates excess TNF. Etanercept is FDA approved to treat a number of immune-mediated disorders and is used off label in the study.. . .
“It is unprecedented that we can see cognitive and behavioral improvement in a patient with established dementia within minutes of therapeutic intervention,” said [Dr. Sue] Griffin [director of research at the Donald W. Reynolds Institute on Aging at the University of Arkansas for Medical Sciences (UAMS)]. “It is imperative that the medical and scientific communities immediately undertake to further investigate and characterize the physiologic mechanisms involved. This gives all of us in Alzheimer’s research a tremendous new clue about new avenues of research, which is so exciting and so needed in the field of Alzheimer’s. Even though this report predominantly discusses a single patient, it is of significant scientific interest because of the potential insight it may give into the processes involved in the brain dysfunction of Alzheimer’s.”
This is a development to watch.